LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 10

Search options

  1. Article ; Online: Study protocol comparing the ethical, psychological and socio-economic impact of personalised breast cancer screening to that of standard screening in the "My Personal Breast Screening" (MyPeBS) randomised clinical trial.

    Roux, Alexandra / Cholerton, Rachel / Sicsic, Jonathan / Moumjid, Nora / French, David P / Giorgi Rossi, Paolo / Balleyguier, Corinne / Guindy, Michal / Gilbert, Fiona J / Burrion, Jean-Benoit / Castells, Xavier / Ritchie, David / Keatley, Debbie / Baron, Camille / Delaloge, Suzette / de Montgolfier, Sandrine

    BMC cancer

    2022  Volume 22, Issue 1, Page(s) 507

    Abstract: Background: The MyPeBS study is an ongoing randomised controlled trial testing whether a risk-stratified breast cancer screening strategy is non-inferior, or eventually superior, to standard age-based screening at reducing incidence of stage 2 or more ... ...

    Abstract Background: The MyPeBS study is an ongoing randomised controlled trial testing whether a risk-stratified breast cancer screening strategy is non-inferior, or eventually superior, to standard age-based screening at reducing incidence of stage 2 or more cancers. This large European Commission-funded initiative aims to include 85,000 women aged 40 to 70 years, without prior breast cancer and not previously identified at high risk in six countries (Belgium, France, Italy, Israel, Spain, UK). A specific work package within MyPeBS examines psychological, socio-economic and ethical aspects of this new screening strategy. It compares women's reported data and outcomes in both trial arms on the following issues: general anxiety, cancer-related worry, understanding of breast cancer screening strategy and information-seeking behaviour, socio-demographic and economic characteristics, quality of life, risk perception, intention to change health-related behaviours, satisfaction with the trial.
    Methods: At inclusion, 3-months, 1-year and 4-years, each woman participating in MyPeBS is asked to fill online questionnaires. Descriptive statistics, bivariate analyses, subgroup comparisons and analysis of variations over time will be performed with appropriate tests to assess differences between arms. Multivariate regression models will allow modelling of different patient reported data and outcomes such as comprehension of the information provided, general anxiety or cancer worry, and information seeking behaviour. In addition, a qualitative study (48 semi-structured interviews conducted in France and in the UK with women randomised in the risk-stratified arm), will help further understand participants' acceptability and comprehension of the trial, and their experience of risk assessment.
    Discussion: Beyond the scientific and medical objectives of this clinical study, it is critical to acknowledge the consequences of such a paradigm shift for women. Indeed, introducing a risk-based screening relying on individual biological differences also implies addressing non-biological differences (e.g. social status or health literacy) from an ethical perspective, to ensure equal access to healthcare. The results of the present study will facilitate making recommendations on implementation at the end of the trial to accompany any potential change in screening strategy.
    Trial registration: Study sponsor: UNICANCER. My personalised breast screening (MyPeBS).
    Clinicaltrials: gov (2018) available at: https://clinicaltrials.gov/ct2/show/NCT03672331 Contact: Cécile VISSAC SABATIER, PhD, + 33 (0)1 73 79 77 58 ext + 330,142,114,293, contact@mypebs.eu.
    MeSH term(s) Adult ; Aged ; Breast Neoplasms/diagnosis ; Early Detection of Cancer/methods ; Female ; Humans ; Mass Screening ; Middle Aged ; Quality of Life ; Randomized Controlled Trials as Topic ; Socioeconomic Factors
    Language English
    Publishing date 2022-05-06
    Publishing country England
    Document type Clinical Trial Protocol ; Journal Article
    ZDB-ID 2041352-X
    ISSN 1471-2407 ; 1471-2407
    ISSN (online) 1471-2407
    ISSN 1471-2407
    DOI 10.1186/s12885-022-09484-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Patient-Derived Xenograft and Cell Line Models of Human Primary Cutaneous Diffuse Large B-Cell Lymphoma-Leg Type.

    Prochazkova-Carlotti, Martina / Gros, Audrey / Richard, Elodie / Cherrier, Floriane / Laharanne, Elodie / Idrissi, Yamina / Baron, Camille / Poglio, Sandrine / Ducharme, Océane / Menguy, Sarah / Pham-Ledard, Anne / Beylot-Barry, Marie / Merlio, Jean-Philippe / Bresson-Bepoldin, Laurence

    The Journal of investigative dermatology

    2022  Volume 143, Issue 2, Page(s) 340–344.e6

    MeSH term(s) Humans ; Animals ; Leg ; Heterografts ; Skin Neoplasms/genetics ; Lymphoma, Large B-Cell, Diffuse/genetics ; Cell Line ; Disease Models, Animal
    Language English
    Publishing date 2022-09-07
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80136-7
    ISSN 1523-1747 ; 0022-202X
    ISSN (online) 1523-1747
    ISSN 0022-202X
    DOI 10.1016/j.jid.2022.08.043
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Validation of a new fully automated software for 2D digital mammographic breast density evaluation in predicting breast cancer risk.

    Giorgi Rossi, Paolo / Djuric, Olivera / Hélin, Valerie / Astley, Susan / Mantellini, Paola / Nitrosi, Andrea / Harkness, Elaine F / Gauthier, Emilien / Puliti, Donella / Balleyguier, Corinne / Baron, Camille / Gilbert, Fiona J / Grivegnée, André / Pattacini, Pierpaolo / Michiels, Stefan / Delaloge, Suzette

    Scientific reports

    2021  Volume 11, Issue 1, Page(s) 19884

    Abstract: We compared accuracy for breast cancer (BC) risk stratification of a new fully automated system (DenSeeMammo-DSM) for breast density (BD) assessment to a non-inferiority threshold based on radiologists' visual assessment. Pooled analysis was performed on ...

    Abstract We compared accuracy for breast cancer (BC) risk stratification of a new fully automated system (DenSeeMammo-DSM) for breast density (BD) assessment to a non-inferiority threshold based on radiologists' visual assessment. Pooled analysis was performed on 14,267 2D mammograms collected from women aged 48-55 years who underwent BC screening within three studies: RETomo, Florence study and PROCAS. BD was expressed through clinical Breast Imaging Reporting and Data System (BI-RADS) density classification. Women in BI-RADS D category had a 2.6 (95% CI 1.5-4.4) and a 3.6 (95% CI 1.4-9.3) times higher risk of incident and interval cancer, respectively, than women in the two lowest BD categories. The ability of DSM to predict risk of incident cancer was non-inferior to radiologists' visual assessment as both point estimate and lower bound of 95% CI (AUC 0.589; 95% CI 0.580-0.597) were above the predefined visual assessment threshold (AUC 0.571). AUC for interval (AUC 0.631; 95% CI 0.623-0.639) cancers was even higher. BD assessed with new fully automated method is positively associated with BC risk and is not inferior to radiologists' visual assessment. It is an even stronger marker of interval cancer, confirming an appreciable masking effect of BD that reduces mammography sensitivity.
    MeSH term(s) Adult ; Area Under Curve ; Automation ; Breast Density ; Breast Neoplasms/diagnostic imaging ; Breast Neoplasms/pathology ; Case-Control Studies ; Early Detection of Cancer/methods ; Female ; Humans ; Image Processing, Computer-Assisted/methods ; Mammography/methods ; Middle Aged ; Radiographic Image Interpretation, Computer-Assisted/methods ; Reproducibility of Results ; Risk ; Software
    Language English
    Publishing date 2021-10-06
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-021-99433-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1.

    Stirnemann, Jérôme / Rose, Christian / Serratrice, Christine / Dalbies, Florence / Lidove, Olivier / Masseau, Agathe / Pers, Yves-Marie / Baron, Camille / Belmatoug, Nadia

    Orphanet journal of rare diseases

    2015  Volume 10, Page(s) 62

    Abstract: Background: In 2009, a worldwide supply constraint of imiglucerase led to treatment modifications or interruptions for patients with Gaucher disease (GD) type 1. In France, joint treatment recommendations were issued to protect the most vulnerable ... ...

    Abstract Background: In 2009, a worldwide supply constraint of imiglucerase led to treatment modifications or interruptions for patients with Gaucher disease (GD) type 1. In France, joint treatment recommendations were issued to protect the most vulnerable patients. This observational study evaluated the impact of imiglucerase treatment modifications on the clinical and biological course of GD.
    Methods: Retrospective data on patients' characteristics, treatment, clinical and biological parameters from 01 June 2009 to 31 October 2010 were collected during a single visit.
    Results: Ninety-nine GD1 patients, aged 7-84 years, were included (median age 47 years); 10 were children. Patients experienced a median of 4 different treatment modifications. Median change from pre-supply constraint dose (92 U/kg/4-weeks) was -69, -51, -29 and -60 U/kg/4-weeks at 3, 6, 9 and 12 months after first modification, respectively, with imiglucerase discontinuation reported for 70%, 47%, 29% and 55% of patients at these timepoints. Replacement with another ERT was reported for 35 patients. Results show a statistically significant decrease in hemoglobin (-0.8 g/L/month) and platelets (-5905.10(3)/mm(3)/month) and an increase in chitotriosidase (+537 nmol/mL/h/month) and angiotensin-converting enzyme (+4 IU/L/month) in the subgroup of 61 patients who discontinued treatment for at least 3 months; this magnitude of change was not seen in the subgroup (32 patients) treated with reduced imiglucerase for at least 3 consecutive months. GD-related events were spontaneously reported by the study investigators for 39% of the whole study population, including asthenia/fatigue (8%), bone infarction and bone pain (4% each), and hepatomegaly (3%). A Kaplan-Meier estimate of the probability for a patient to present a bone, hematological or visceral event during the constraint was 37% for patients who discontinued the treatment and 10% for patients treated with a reduced imiglucerase dose.
    Conclusion: The release of recommendations and individuals' close follow-up allowed satisfactory management of patients during the imiglucerase supply constraint in France. This study suggests that during this period, lowering the dose of imiglucerase had less impact on the outcomes of patients than interrupting treatment. However, general effects (such as fatigue, bone pain) reported in some patients, emphasize the importance of maintaining appropriate individualized dosing.
    MeSH term(s) Adolescent ; Adult ; Aged ; Aged, 80 and over ; Child ; Enzyme Replacement Therapy ; France/epidemiology ; Gaucher Disease/drug therapy ; Glucosylceramidase/supply & distribution ; Glucosylceramidase/therapeutic use ; Humans ; Middle Aged ; Retrospective Studies ; Treatment Outcome ; Young Adult
    Chemical Substances Glucosylceramidase (EC 3.2.1.45) ; imiglucerase (Q6U6J48BWY)
    Language English
    Publishing date 2015-05-13
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 1750-1172
    ISSN (online) 1750-1172
    DOI 10.1186/s13023-015-0275-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement.

    Pashayan, Nora / Antoniou, Antonis C / Ivanus, Urska / Esserman, Laura J / Easton, Douglas F / French, David / Sroczynski, Gaby / Hall, Per / Cuzick, Jack / Evans, D Gareth / Simard, Jacques / Garcia-Closas, Montserrat / Schmutzler, Rita / Wegwarth, Odette / Pharoah, Paul / Moorthie, Sowmiya / De Montgolfier, Sandrine / Baron, Camille / Herceg, Zdenko /
    Turnbull, Clare / Balleyguier, Corinne / Rossi, Paolo Giorgi / Wesseling, Jelle / Ritchie, David / Tischkowitz, Marc / Broeders, Mireille / Reisel, Dan / Metspalu, Andres / Callender, Thomas / de Koning, Harry / Devilee, Peter / Delaloge, Suzette / Schmidt, Marjanka K / Widschwendter, Martin

    Nature reviews. Clinical oncology

    2020  Volume 17, Issue 11, Page(s) 716

    Abstract: An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...

    Abstract An amendment to this paper has been published and can be accessed via a link at the top of the paper.
    Language English
    Publishing date 2020-06-15
    Publishing country England
    Document type Published Erratum
    ZDB-ID 2491410-1
    ISSN 1759-4782 ; 1759-4774
    ISSN (online) 1759-4782
    ISSN 1759-4774
    DOI 10.1038/s41571-020-0412-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Personalized early detection and prevention of breast cancer: ENVISION consensus statement.

    Pashayan, Nora / Antoniou, Antonis C / Ivanus, Urska / Esserman, Laura J / Easton, Douglas F / French, David / Sroczynski, Gaby / Hall, Per / Cuzick, Jack / Evans, D Gareth / Simard, Jacques / Garcia-Closas, Montserrat / Schmutzler, Rita / Wegwarth, Odette / Pharoah, Paul / Moorthie, Sowmiya / De Montgolfier, Sandrine / Baron, Camille / Herceg, Zdenko /
    Turnbull, Clare / Balleyguier, Corinne / Rossi, Paolo Giorgi / Wesseling, Jelle / Ritchie, David / Tischkowitz, Marc / Broeders, Mireille / Reisel, Dan / Metspalu, Andres / Callender, Thomas / de Koning, Harry / Devilee, Peter / Delaloge, Suzette / Schmidt, Marjanka K / Widschwendter, Martin

    Nature reviews. Clinical oncology

    2020  Volume 17, Issue 11, Page(s) 687–705

    Abstract: The European Collaborative on Personalized Early Detection and Prevention of Breast Cancer (ENVISION) brings together several international research consortia working on different aspects of the personalized early detection and prevention of breast ... ...

    Abstract The European Collaborative on Personalized Early Detection and Prevention of Breast Cancer (ENVISION) brings together several international research consortia working on different aspects of the personalized early detection and prevention of breast cancer. In a consensus conference held in 2019, the members of this network identified research areas requiring development to enable evidence-based personalized interventions that might improve the benefits and reduce the harms of existing breast cancer screening and prevention programmes. The priority areas identified were: 1) breast cancer subtype-specific risk assessment tools applicable to women of all ancestries; 2) intermediate surrogate markers of response to preventive measures; 3) novel non-surgical preventive measures to reduce the incidence of breast cancer of poor prognosis; and 4) hybrid effectiveness-implementation research combined with modelling studies to evaluate the long-term population outcomes of risk-based early detection strategies. The implementation of such programmes would require health-care systems to be open to learning and adapting, the engagement of a diverse range of stakeholders and tailoring to societal norms and values, while also addressing the ethical and legal issues. In this Consensus Statement, we discuss the current state of breast cancer risk prediction, risk-stratified prevention and early detection strategies, and their implementation. Throughout, we highlight priorities for advancing each of these areas.
    MeSH term(s) Breast Neoplasms/diagnosis ; Breast Neoplasms/genetics ; Breast Neoplasms/prevention & control ; Consensus ; Early Detection of Cancer ; Evidence-Based Medicine ; Female ; Genetic Predisposition to Disease ; Humans ; Mass Screening ; Precision Medicine
    Language English
    Publishing date 2020-06-18
    Publishing country England
    Document type Consensus Development Conference ; Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2491410-1
    ISSN 1759-4782 ; 1759-4774
    ISSN (online) 1759-4782
    ISSN 1759-4774
    DOI 10.1038/s41571-020-0388-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Personalized early detection and prevention of breast cancer

    Pashayan, Nora / Antoniou, Antonis C. / Ivanus, Urska / Esserman, Laura J. / Easton, Douglas F. / French, David / Sroczynski, Gaby / Hall, Per / Cuzick, Jack / Evans, D. Gareth / Simard, Jacques / Garcia-Closas, Montserrat / Schmutzler, Rita / Wegwarth, Odette / Pharoah, Paul / Moorthie, Sowmiya / De Montgolfier, Sandrine / Baron, Camille / Herceg, Zdenko /
    Turnbull, Clare / Balleyguier, Corinne / Rossi, Paolo Giorgi / Wesseling, Jelle / Ritchie, David / Tischkowitz, Marc / Broeders, Mireille / Reisel, Dan / Metspalu, Andres / Callender, Thomas / de Koning, Harry / Devilee, Peter / Delaloge, Suzette / Schmidt, Marjanka K. / Widschwendter, Martin

    Nature Reviews Clinical Oncology

    ENVISION consensus statement

    2020  Volume 17, Issue 11, Page(s) 687–705

    Abstract: The European Collaborative on Personalized Early Detection and Prevention of Breast Cancer (ENVISION) brings together several international research consortia working on different aspects of the personalized early detection and prevention of breast ... ...

    Title translation Personalisierte Früherkennung und Prävention von Brustkrebs: ENVISION Konsenserklärung
    Abstract The European Collaborative on Personalized Early Detection and Prevention of Breast Cancer (ENVISION) brings together several international research consortia working on different aspects of the personalized early detection and prevention of breast cancer. In a consensus conference held in 2019, the members of this network identified research areas requiring development to enable evidence-based personalized interventions that might improve the benefits and reduce the harms of existing breast cancer screening and prevention programmes. The priority areas identified were: 1) breast cancer subtype-specific risk assessment tools applicable to women of all ancestries; 2) intermediate surrogate markers of response to preventive measures; 3) novel non-surgical preventive measures to reduce the incidence of breast cancer of poor prognosis; and 4) hybrid effectiveness-implementation research combined with modelling studies to evaluate the long-term population outcomes of risk-based early detection strategies. The implementation of such programmes would require health-care systems to be open to learning and adapting, the engagement of a diverse range of stakeholders and tailoring to societal norms and values, while also addressing the ethical and legal issues. In this Consensus Statement, we discuss the current state of breast cancer risk prediction, risk-stratified prevention and early detection strategies, and their implementation. Throughout, we highlight priorities for advancing each of these areas.
    Keywords Breast ; Brust ; Cancer Screening ; Krebskrankheit ; Krebsvorsorgeuntersuchung ; Neoplasms ; Prediction ; Prevention ; Prävention ; Risikoerfassung ; Risk Assessment ; Strategien ; Strategies ; Vorhersage
    Language English
    Document type Article
    ZDB-ID 2491410-1
    ISSN 1759-4782 ; 1759-4782 ; 1759-4774
    ISSN (online) 1759-4782
    ISSN 1759-4782 ; 1759-4774
    DOI 10.1038/s41571-020-0388-9
    Database PSYNDEX

    More links

    Kategorien

  8. Article ; Online: Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer.

    Bisiaux, Aurélie / Thiounn, Nicolas / Timsit, Marc-Olivier / Eladaoui, Ahmed / Chang, Huey-Hsuan / Mapes, James / Mogenet, Agnès / Bresson, Jean-Louis / Prié, Dominique / Béchet, Stéphane / Baron, Camille / Sadorge, Christine / Thomas, Stéphanie / Albert, Elaine B / Albert, Peter S / Albert, Matthew L

    The Journal of urology

    2009  Volume 181, Issue 4, Page(s) 1571–1580

    Abstract: Purpose: We characterized the innate immune response to intravesical bacillus Calmette-Guerin therapy using a systems approach based on proteomic and cytometric screens.: Materials and methods: Blood and urine were collected from patients receiving ... ...

    Abstract Purpose: We characterized the innate immune response to intravesical bacillus Calmette-Guerin therapy using a systems approach based on proteomic and cytometric screens.
    Materials and methods: Blood and urine were collected from patients receiving intravesical bacillus Calmette-Guerin therapy before, and 2 and 4 hours after bacillus Calmette-Guerin treatment, at the first and third instillation. Proteomic and cytometry based screens were performed.
    Results: Molecular analyte profiling revealed a prime/boost pattern to the innate response to intravesical bacillus Calmette-Guerin. We identified 36 statistically significant changes in the proteins induced during the third instillation compared to the initial treatment. These analytes were classified into 3 categories of 1) plasma proteins that leaked into the urine, 2) cytokines/chemokines produced locally during the first hours of inflammation and 3) other innate molecules that modulate the bladder microenvironment. To characterize the marked increase in the inflammatory response after multiple treatments we evaluated the cells present in the urine and again a prime/boost response was revealed. For the locally produced analytes it was possible to define the cell source(s) and, thus, provide a first generation map of what occurs during the initial phase of bacillus Calmette-Guerin therapy.
    Conclusions: This study provides in vivo information concerning the ability of bacillus Calmette-Guerin to sensitize the tissue microenvironment to enhance innate responses and establishes a framework for improving vaccination strategies while decreasing adverse events.
    MeSH term(s) Adjuvants, Immunologic/administration & dosage ; Administration, Intravesical ; Aged ; BCG Vaccine/administration & dosage ; Female ; Flow Cytometry ; Humans ; Male ; Middle Aged ; Proteomics ; Time Factors ; Urinary Bladder Neoplasms/blood ; Urinary Bladder Neoplasms/drug therapy ; Urinary Bladder Neoplasms/urine
    Chemical Substances Adjuvants, Immunologic ; BCG Vaccine
    Language English
    Publishing date 2009-04
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 3176-8
    ISSN 1527-3792 ; 0022-5347
    ISSN (online) 1527-3792
    ISSN 0022-5347
    DOI 10.1016/j.juro.2008.11.124
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Profiling of tannins, flavonoids and hydroxycinnamic esters in the fruits of a cider apple progeny

    Marnet, Nathalie / Childebrand, Nicolas / Le Bail, Gildas / Leroux, Alexandra / Mabon, Romain / BARON, Camille / Le Quéré, Jean-Michel / Verdu, Cindy / Laurens, Francois / Lespinasse, Yves

    Sixièmes Journées Scientifiques du Réseau Français de Métabolomique et Fluxomique . 2012; 6. Journées Scientifiques RFMF, Nantes, FRA, 2012-05-21-2012-05-23, 70

    Language English
    Document type Article
    Database AGRIS - International Information System for the Agricultural Sciences and Technology

    More links

    Kategorien

  10. Article: Profiling of tannins, flavonoids and hydroxycinnamic esters in the fruits of a cider apple progeny

    Marnet, Nathalie / Childebrand, Nicolas / Le Bail, Gildas / Leroux, Alexandra / Mabon, Romain / BARON, Camille / Le Quéré, Jean-Michel / Verdu, Cindy / Laurens, Francois / Lespinasse, Yves

    Sixièmes Journées Scientifiques du Réseau Français de Métabolomique et Fluxomique . 2012; 6. Journées Scientifiques RFMF, Nantes, FRA, 2012-05-21-2012-05-23, 70

    Language English
    Document type Article
    Database AGRIS - International Information System for the Agricultural Sciences and Technology

    More links

    Kategorien

To top